Sugi Predict

Sugi Predict / Compounds / SCHEMBL381027

SCHEMBL381027

SCHEMBL381027

CC(=O)c1ccc(F)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CES2 O00748 1/20 0.43
▸ CES1 P23141 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAOB P27338 3/20 0.42
▸ MAOA P21397 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KIF11 P52732 1/20 0.42
▸ CYP2A6 P11509 1/20 0.41
▸ PKM P14618 2/20 0.41
▸ IDO1 P14902 1/20 0.40
▸ PGR P06401 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL29051483 0.93 PKM (0.43) NPC1RAB9ASMN1; SMN2CES2CES1
SCHEMBL333891 0.83 ALDH1A1 (0.47) NPC1RAB9ACES2CES1ALDH1A1
SCHEMBL29620496 0.83 ALDH1A1 (0.47) NPC1RAB9ACES2CES1ALDH1A1
SCHEMBL16957665 0.83 IDO1 (0.39) NPC1RAB9ACES2CES1ALDH1A1
SCHEMBL30817696 0.83 ALDH1A1 (0.52) NPC1RAB9ACES2CES1ALDH1A1
SCHEMBL31302316 0.81 TTR (0.50) NPC1RAB9ACES2CES1MAOB
SCHEMBL9215548 0.81 NPC1 (0.47) NPC1RAB9ACES2CES1ALDH1A1
SCHEMBL104151 0.81 TTR (0.50) NPC1RAB9ACES2CES1MAOB
SCHEMBL10555693 0.81 CES2 (0.45) NPC1RAB9ACES2CES1ALDH1A1
SCHEMBL29669896 0.80 CES2 (0.67) NPC1RAB9ACES2CES1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116425782-A Preparation method of 5-acetyl-2-fluorobenzeneboronic acid pinacol ester 烟台盛凯伦化学科技有限公司 2023-07-14 — — CN claimed
CN-116144617-A NADH dependent alcohol dehydrogenase CpSADH, coding gene, strain and application 浙江工业大学 2023-05-23 — — CN claimed
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 — — US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
US-20250276978-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2025-09-04 — — US disclosed
EP-3954685-B1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF US HEALTH (US) 2025-08-27 — — EP disclosed
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2025-07-22 — — US disclosed
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety CURIS INC (US) 2025-07-17 — — US disclosed
US-20250205203-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS PHARMA AG (CH) 2025-06-26 — — US disclosed
CN-120058445-A Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method 华东师范大学 2025-05-30 — — CN disclosed
WO-1997036860-A1 CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-10-09 — — WO disclosed
EP-0588785-A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-03-30 — — EP disclosed
US-5185363-A Administering for treatment of inflammatory diseases ABBOTT LABORATORIES (US) 1993-02-09 — — US disclosed
EP-0500493-A1 Novel poly(arylene etherketones) CIBA-GEIGY AG (CH) 1992-08-26 — — EP disclosed
EP-0588785-A4 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1991-12-30 — — EP disclosed
WO-1990012008-A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1990-10-18 — — WO disclosed
US-4446075-A DIRECT BROMINATION RIEDEL-DE HAEN AG (DE) 1984-05-01 — — US disclosed
EP-0034741-B1 PROCESS FOR THE PREPARATION OF A SUBSTITUTED BROMOFLUOROBENZENE AND 3-BROMO-4-FLUOROBENZONITRILE RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1983-12-21 — — EP disclosed
EP-0034741-A2 Process for the preparation of a substituted bromofluorobenzene and 3-bromo-4-fluorobenzonitrile RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) 1981-09-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 NPC1 978/4885RAB9A 1314/4885SMN1; SMN2 1858/4885
US-20250276978-A1 HETEROCYCLIC COMPOUNDS AS BET INHIBITORS BET1, BRD4, BRD3 NPC1 2080/4885RAB9A 2560/4885SMN1; SMN2 2600/4885
US-20250230169-A1 Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety BAZ2A, BAZ2B, PI4KB NPC1 2404/4885RAB9A 2340/4885SMN1; SMN2 4184/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 NPC1 1729/4885RAB9A 957/4885SMN1; SMN2 3398/4885
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHA1 NPC1 3236/4885RAB9A 2425/4885SMN1; SMN2 3199/4885
US-20250205203-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF LDHA, LDHB, XDH NPC1 1875/4885RAB9A 3319/4885SMN1; SMN2 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.